{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-100131","form_type":"8-K","ticker":"ARTV","cik":"0001817241","company_name":"Artiva Biotherapeutics, Inc.","filed_at":"2026-03-10T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.287588+00:00","generated_at":"2026-05-15T16:54:48.997837+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Artiva reports FY2025 net loss of $83.9M; cash $108M into Q2 2027","bullets":["Net loss $83.9M vs $65.4M in 2024; R&D spend $69.5M (up 38% YoY); revenue zero.","Cash, equivalents and investments $108.0M as of Dec 31, 2025, expected to fund operations into Q2 2027.","AlloNK for refractory RA: initial clinical response data from ≥15 patients expected H1 2026; FDA Fast Track granted.","Planned FDA interaction in H1 2026 to discuss potential pivotal trial design for AlloNK in refractory RA.","Appointed Subhashis Banerjee, M.D. as CMO and Thad Huston as CFO; added two board members with immunology/commercial expertise."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-100131","json":"https://secwatch.observer/filing/0001193125-26-100131.json","markdown":"https://secwatch.observer/filing/0001193125-26-100131.md","text":"https://secwatch.observer/filing/0001193125-26-100131.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1817241/000119312526100131/0001193125-26-100131-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1817241/000119312526100131/artv-20260310.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T16:54:48.997837+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8020b1de0749f92a18446a66a106310c0829b6fa","claim":"Artiva Biotherapeutics, Inc. reported the year ended December 31, 2025 results: revenue zero, net income Net loss totaled $83.9 million.","evidence_excerpt":"On March 10, 2026, Artiva Biotherapeutics, Inc. (“Artiva”) issued a press release announcing its financial results for the year ended December 31, 2025.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1817241/000119312526100131/0001193125-26-100131-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2025"},{"label":"Revenue","value":"zero"},{"label":"Net income","value":"Net loss totaled $83.9 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}